José Marcos Vieira de Albuquerque Filho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
José Marcos Vieira de Albuquerque Filho has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Paulo Victor Sgobbi de Souza
Division of Neuromuscular Diseases, Department of Neurology and Neurosurgery, Federal University of São Paulo (UNIFESP), São Paulo 04039-060, Brazil
4 shared publications - Wladimir Bocca Vieira de Rezende Pinto
Neurometabolic Unit, Division of Neuromuscular Diseases, Department of Neurology and Neurosurgery, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil
4 shared publications - Acary Souza Bulle Oliveira
Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo SP, Brazil
3 shared publications - Igor Braga Farias
Universidade Federal de São Paulo, Brazil
3 shared publications - Bruno de Mattos Lombardi Badia
Porphyria Unit, Division of Neuromuscular Diseases, Federal University of São Paulo (UNIFESP), São Paulo 04039-060, SP, Brazil
2 shared publications - Roberta Ismael Lacerda Machado
Universidade Federal de São Paulo, Brazil
2 shared publications
Latest Publications
- 2 May 2022
- Published by Georg Thieme Verlag KG in Journal of Pediatric Genetics
- Vol. 12 (04) , 301-307
Clinical and Genetic Aspects of Childhood-Onset Demyelinating Charcot–Marie–Tooth's Disease in Brazil
Charcot–Marie–Tooth's disease (CMT) represents the most common inherited neuropathy. Most patients are diagnosed during late stages of disease course during adulthood. We performed a review of clinical, neurophysiological, and genetic diagnoses of 32 patients with genetically defined childhood-onset demyelinating CMT under clinical follow-up in a Brazilian Center for Neuromuscular Diseases from January 2015 to December 2019. The current mean age was 33.1 ± 18.3 years (ranging from 7 to 71 years) and mean age at defined genetic diagnosis was 36.1 ± 18.3 years. The mean age at onset was 6.1 ± 4.4 years. The most common initial complaint was bilateral pes cavus. The genetic basis included PMP22 duplication (CMT1A) (n = 18), GJB1 (CMTX1) (n = 5), MPZ (CMT1B) (n = 3), FIG4 (CMT4J) (n = 3), SH3TC2 (CMT4C) (n = 1), PLEKHG5 (CMTRIC) (n = 1), and PRX (CMT4F) (n = 1). Almost all patients (n = 31) presented with moderate or severe compromise in the CMT neuropathy score 2 with the highest values observed in CMT1B. Medical history disclosed obstructive sleep apnea (n = 5), aseptic meningitis (n = 1/MPZ), akinetic-rigid parkinsonism (n = 1/FIG4), and overlapping chronic inflammatory demyelinating polyneuropathy (n = 1/MPZ). Motor conduction block was detected in three individuals (PMP22, FIG4, MPZ). Acute denervation occurred in seven patients. Nonuniform demyelinating patterns were seen in four individuals (two CMT1A, one CMT1B, and one CMTX1). Abnormal cerebral white matter findings were detected in CMT1A and CMTX1, while hypertrophic roots were seen in CMT1A, CMT1B, and CMTX1. Our study emphasizes a relative oligogenic basis in childhood-onset demyelinating CMT and atypical findings may be observed especially in MPZ, PMP22, and GJB1 gene variants.
- 2 May 2022
- Published by Georg Thieme Verlag KG in Journal of Pediatric Genetics
- Vol. 12 (04) , 301-307
Clinical and Genetic Aspects of Childhood-Onset Demyelinating Charcot–Marie–Tooth's Disease in Brazil
Charcot–Marie–Tooth's disease (CMT) represents the most common inherited neuropathy. Most patients are diagnosed during late stages of disease course during adulthood. We performed a review of clinical, neurophysiological, and genetic diagnoses of 32 patients with genetically defined childhood-onset demyelinating CMT under clinical follow-up in a Brazilian Center for Neuromuscular Diseases from January 2015 to December 2019. The current mean age was 33.1 ± 18.3 years (ranging from 7 to 71 years) and mean age at defined genetic diagnosis was 36.1 ± 18.3 years. The mean age at onset was 6.1 ± 4.4 years. The most common initial complaint was bilateral pes cavus. The genetic basis included PMP22 duplication (CMT1A) (n = 18), GJB1 (CMTX1) (n = 5), MPZ (CMT1B) (n = 3), FIG4 (CMT4J) (n = 3), SH3TC2 (CMT4C) (n = 1), PLEKHG5 (CMTRIC) (n = 1), and PRX (CMT4F) (n = 1). Almost all patients (n = 31) presented with moderate or severe compromise in the CMT neuropathy score 2 with the highest values observed in CMT1B. Medical history disclosed obstructive sleep apnea (n = 5), aseptic meningitis (n = 1/MPZ), akinetic-rigid parkinsonism (n = 1/FIG4), and overlapping chronic inflammatory demyelinating polyneuropathy (n = 1/MPZ). Motor conduction block was detected in three individuals (PMP22, FIG4, MPZ). Acute denervation occurred in seven patients. Nonuniform demyelinating patterns were seen in four individuals (two CMT1A, one CMT1B, and one CMTX1). Abnormal cerebral white matter findings were detected in CMT1A and CMTX1, while hypertrophic roots were seen in CMT1A, CMT1B, and CMTX1. Our study emphasizes a relative oligogenic basis in childhood-onset demyelinating CMT and atypical findings may be observed especially in MPZ, PMP22, and GJB1 gene variants.
- Open Access
- 1 November 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (11) , 1012-1025
Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.
- 1 November 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (11) , 1012-1025
Open AccessImmunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy
For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.
- Open Access
- 1 October 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (10) , 912-923
Adult-onset non-5q proximal spinal muscular atrophy: a comprehensive review
Background: Adult-onset spinal muscular atrophy (SMA) represents an expanding group of inherited neurodegenerative disorders in clinical practice. Objective: This review aims to synthesize the main clinical, genetic, radiological, biochemical, and neurophysiological aspects related to the classical and recently described forms of proximal SMA. Methods: The authors performed a non-systematic critical review summarizing adult-onset proximal SMA presentations. Results: Previously limited to cases of SMN1-related SMA type 4 (adult form), this group has now more than 15 different clinical conditions that have in common the symmetrical and progressive compromise of lower motor neurons starting in adulthood or elderly stage. New clinical and genetic subtypes of adult-onset proximal SMA have been recognized and are currently target of wide neuroradiological, pathological, and genetic studies. Conclusions: This new complex group of rare disorders typically present with lower motor neuron disease in association with other neurological or systemic signs of impairment, which are relatively specific and typical for each genetic subtype.
- 1 October 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (10) , 912-923
Open AccessAdult-onset non-5q proximal spinal muscular atrophy: a comprehensive review
Background: Adult-onset spinal muscular atrophy (SMA) represents an expanding group of inherited neurodegenerative disorders in clinical practice. Objective: This review aims to synthesize the main clinical, genetic, radiological, biochemical, and neurophysiological aspects related to the classical and recently described forms of proximal SMA. Methods: The authors performed a non-systematic critical review summarizing adult-onset proximal SMA presentations. Results: Previously limited to cases of SMN1-related SMA type 4 (adult form), this group has now more than 15 different clinical conditions that have in common the symmetrical and progressive compromise of lower motor neurons starting in adulthood or elderly stage. New clinical and genetic subtypes of adult-onset proximal SMA have been recognized and are currently target of wide neuroradiological, pathological, and genetic studies. Conclusions: This new complex group of rare disorders typically present with lower motor neuron disease in association with other neurological or systemic signs of impairment, which are relatively specific and typical for each genetic subtype.
- Open Access
- 21 May 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (5) , 465-466
Neuromuscular choristoma: a rare cause of congenital non-progressive lower limb amyotrophy
NMCs of the sciatic nerves, formerly known as neuromuscular hamartomas, are rare tumors with mature skeletal muscle and neural elements1,2. Typical imaging features are important for differential diagnosis, especially in cases with congenital long-standing involvement and monomelic amyotrophy, avoiding unnecessary biopsy and the risk of developing aggressive fibromatosis1,2.
- 21 May 2021
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 79 (5) , 465-466
Open AccessNeuromuscular choristoma: a rare cause of congenital non-progressive lower limb amyotrophy
NMCs of the sciatic nerves, formerly known as neuromuscular hamartomas, are rare tumors with mature skeletal muscle and neural elements1,2. Typical imaging features are important for differential diagnosis, especially in cases with congenital long-standing involvement and monomelic amyotrophy, avoiding unnecessary biopsy and the risk of developing aggressive fibromatosis1,2.